1. Home
  2. CERO vs LICN Comparison

CERO vs LICN Comparison

Compare CERO & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • LICN
  • Stock Information
  • Founded
  • CERO 2017
  • LICN 2004
  • Country
  • CERO United States
  • LICN China
  • Employees
  • CERO N/A
  • LICN N/A
  • Industry
  • CERO
  • LICN
  • Sector
  • CERO
  • LICN
  • Exchange
  • CERO Nasdaq
  • LICN Nasdaq
  • Market Cap
  • CERO 3.5M
  • LICN 3.6M
  • IPO Year
  • CERO N/A
  • LICN 2023
  • Fundamental
  • Price
  • CERO $9.93
  • LICN $4.25
  • Analyst Decision
  • CERO Strong Buy
  • LICN
  • Analyst Count
  • CERO 2
  • LICN 0
  • Target Price
  • CERO $45.00
  • LICN N/A
  • AVG Volume (30 Days)
  • CERO 3.3M
  • LICN 75.2K
  • Earning Date
  • CERO 08-13-2025
  • LICN 01-01-0001
  • Dividend Yield
  • CERO N/A
  • LICN N/A
  • EPS Growth
  • CERO N/A
  • LICN N/A
  • EPS
  • CERO N/A
  • LICN N/A
  • Revenue
  • CERO N/A
  • LICN $41,477,000.00
  • Revenue This Year
  • CERO N/A
  • LICN N/A
  • Revenue Next Year
  • CERO N/A
  • LICN N/A
  • P/E Ratio
  • CERO N/A
  • LICN N/A
  • Revenue Growth
  • CERO N/A
  • LICN 4.32
  • 52 Week Low
  • CERO $6.71
  • LICN $2.60
  • 52 Week High
  • CERO $895.40
  • LICN $488.00
  • Technical
  • Relative Strength Index (RSI)
  • CERO 50.09
  • LICN 47.63
  • Support Level
  • CERO $8.12
  • LICN $3.80
  • Resistance Level
  • CERO $13.14
  • LICN $4.26
  • Average True Range (ATR)
  • CERO 2.83
  • LICN 0.33
  • MACD
  • CERO 0.39
  • LICN -0.03
  • Stochastic Oscillator
  • CERO 19.58
  • LICN 37.85

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: